News | June 09, 2021
Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Subscribe To Our Newsletter & Stay Updated
